You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm recently announced a collaboration with Sweden’s Karolinska Institute to test COVID-19 pneumonia patients for bacterial co-infections.
The institute will use Curetis' Unyvero Hospitalized Pneumonia panel on high-risk patients admitted to the ICU for COVID-19 pneumonia.
The company's revenue was largely attributed to its Acuitas AMR Gene Panel and Acuitas Lighthouse informatics platform.
OpGen also reported full-year growth was driven by revenue increases for its Acuitas AMR Gene Panel and Acuitas Lighthouse informatics platform.
OpGen, which is acquiring Curetis, said that combined revenue for both companies would have been about $6 million in 2019 had the deal been completed last year.
The company also inked a deal with an investment bank to publicly offer from time to time up to $4.2 million of its stock.
The deal with Quaphaco includes minimum Unyvero A50 instrument and infectious disease test cartridge purchases of €1.9 million over the initial three-year term.
A subsidiary of Curetis, a firm recently merged with OpGen, Ares will use BGI technology to sequence samples in Europe.
The LRT BAL panel detects a wide spectrum of clinically relevant causative agents, such as atypical pathogens and antibiotic resistance markers.
The company also said that it expects a clearance decision from US regulators in the near term on a lower respiratory tract infection test that runs on its Unyvero system.
Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.
Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.
A new Pew Research Center poll finds confidence in medical researchers has grown among US adults since the start of the coronavirus pandemic.
In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.